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Introduction
The hallmark of autoimmune lymphoproliferative syndrome (ALPS) is non-malignant lymphoproliferation causing severe autoimmunity directed mainly towards blood cells [1] . In a small number of patients with a distinct entity, differing from ALPS, mutations in either neuroblastoma RAS viral (V-Ras) oncogene homologue (NRAS) or Kirsten rat sarcoma viral oncogene homologue (KRAS) have been reported. Mutations in these genes lead to a similar phenotype of non-malignant lymphoproliferation with autoimmune cytopenias. These entities have been designated as RAS-associated lymphoproliferative disease (RALD) [1] [2] [3] [4] . RAS proteins are guanosine diphosphate/guanosine triphosphate (GDP/GTP)-binding proteins that act as intracellular signal transducers, which play a crucial role in normal tissue signalling, including proliferation, differentiation and senescence. Due to their vitality in normal tissue function, mutated RAS genes are extremely potent oncogenes, with mutations in KRAS found in as many as 25% of all human cancers [5] , solid as well as haematological. In contrast, RALD is extremely rare, with only 20 patients described in the literature to date [3, 4, [6] [7] [8] . What drives some RAS mutations to induce benign, non-malignant lymphoproliferation, while others lead to cancer development, is unknown. Some speculate that RALD is a preliminary incarnation of juvenile myelomonocytic leukaemia (JMML), a severe variant of chronic leukaemia, with which RALD shares many clinical and laboratory findings, although the two entities differ substantially in terms of disease course and prognosis [7] .
In both ALPS and RALD, the pathogenesis involves an inability to halt an immune response after it had run its course. In ALPS, reduced apoptosis occurs due to malfunction of the FAS-FAS ligand (FASL) pathway. In RALD, inhibition of apoptosis is mediated by resistance to interleukin (IL)-2 depletion-dependent apoptosis [6] . Whereas both ALPS and RALD patients present with lymphoproliferation and autoimmunity, the elevated ab 1 double-negative T cell (DNT) counts, that are a hallmark of ALPS, are increased only minimally in RALD. Significant T and B cell immunodeficiency leading to an increased susceptibility to infections has yet to be reported and studied thoroughly in RALD.
Here we report a female patient with RALD who presented with autoimmune pancytopenia and was found to harbour a somatic missense mutation in KRAS. Using both traditional immune assays as well as high-throughput sequencing of the immune cell receptor repertoire, we attempt to elucidate the co-existence of autoimmunity and immune deficiency in RALD patients.
Methods

Clinical data
Patient records were obtained from the e-record registry of our hospital. The patient was interviewed and examined by the authors. Informed consent was obtained and all procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Exome sequencing analysis
The Burrows-Wheeler Alignment (BWA) mem algorithm (version 0.7.12) [9] was used for alignment of the sequence reads to the human reference genome (hg19). The HaplotypeCaller algorithm of the Genome Analysis Toolkit (GATK) version 3.4 was applied for variant calling, as recommended in the best practice pipeline [10] KGG-seq version 08 [11] , and was used for annotation of detected variants and inhouse scripts were applied for further filtering.
Immunological evaluation
Lymphocyte subset determination. Cell surface markers of peripheral blood mononuclear cells (PBMCs) were determined by immunofluorescent staining and flow cytometry (Epics V; Coulter Electronics, Hialeah, FL, USA) using anti-CD3, anti-CD19, anti-CD16 and anti-CD56 from BD Biosciences (San Jose, CA, USA) and anti-CD4 and anti-CD8 from Beckman Coulter Immunotech (Brea, CA, USA).
Quantification of signal joint T cell receptor excision circles (sjTRECs), signal joint kappa deleting receptor excision circles (sjKRECs) and intronic recombination signal sequencekappa-deleting element( iRSS-Kde) rearrangements. sjTREC copy numbers were determined using quantitative realtime polymerase chain reaction (qRT-PCR). PCR reactions were performed as described previously [12] using as template 0Á5 mg genomic DNA (gDNA) extracted from the patient's PBMCs. qRT-PCR was carried out using an ABI PRISM 7900 Sequence Detector System (Applied Biosystems, Foster City, CA, USA). A standard curve was constructed using serial dilutions containing 10 3 -10 6 copies of a known sjTREC plasmid. Patient and control samples were tested in triplicate, and the number of sjTRECs in a given sample was calculated by comparing the obtained cycle threshold (Ct) value of the sample to the standard curve using an absolute quantification algorithm. The amount of sjKRECs and iRSS-Kde rearrangements was determined by qRT-PCR, as described previously [12] . The threshold for Ct determination was positioned at the same level each time. Amplification of RNAseP (TaqMan assay; Applied Biosystems) served as a quality control of DNA amplification for both the sjTREC and the sjKREC/iRSS-Kde assays.
Cell surface analysis of T cell receptor (TCR) Vb expression. Surface expression of individual TCR-Vb gene families was analysed using flow cytometry and a set of 24 Vbspecific fluorochrome-labelled monoclonal antibodies (Beckman Coulter), as described previously [13] . Normal control values were obtained from the IOTest Beta MarkQuick Reference Card (Beckman Coulter).
B cell receptor (BCR) repertoire. Complementarity determining region 3 (CDR3) length distribution for a cluster of BCR heavy chain (IGH) V and J gene segment pairings was assessed by means of PCR amplification according to the standardized BIOMED-2 protocol [14] . Fluorescencelabelled PCR products (1 ml) were added to a mixture of 8Á5 ml of formamide and 0Á5 ml of GeneScan 500 Rox internal lane standard (Applied Biosystems) and separated using the 3100 Genetic Analyzer (Applied Biosystems). Results were analysed with Gene Mapper software (Applied Biosystems).
Next-generation sequencing (NGS). TCR and BCR libraries were generated from patient and control genomic DNA using primers for conserved regions of V and J genes in the TRG (TCR-g) and IGH loci, respectively, according to the manufacturer's protocol (Lymphotrack; Invivoscibe Technologies, Carlsbad, CA, USA). Quantified libraries were pooled and sequenced using Mi-Seq Illumia technology. FASTA files from the filtered sequences were submitted to ImMunoGeneTics (IMGT) HighV-QUEST webserver (http://www.imgt.org), filtered for productive sequences only (no stop codons or frame shifts) and analysed [15] . Analyses were performed on CDR3 amino acid sequences. For both BCR and TCR repertoires, V and J gene usage patterns were analysed and repertoire diversity was calculated using several diversity indices, as follows:
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Results
Clinical description
The patient, a 6-year-old girl, was born to second-degree consanguineous parents with a negative family history of immunodeficiency and/or autoimmunity. She was clinically immune deficient from the age of 4 months, suffering from recurrent infections including otitis media, pneumonia, urinary tract infection and herpetic skin infection requiring hospitalizations. At the age of 9 months, she developed hepatosplenomegaly and lymphadenopathy followed by Coombs positive haemolytic anaemia and thrombocytopaenia (Table 1) . Repeated bone marrow aspirations revealed normal cellularity. At the age of 1Á5 years, she developed severe cytomegalovirus (CMV) disease that manifested in severe pneumonia requiring mechanical ventilation for 2 weeks in the paediatric intensive care unit. Following recovery, she continued to suffer from pancytopaenia requiring multiple blood product transfusions. Due to protracted thrombocytopaenia, she was treated with intravenous immunoglobulin, steroids and rapamycin and eventually underwent splenectomy due to a large splenic infarct. An extensive diagnostic work-up to rule out malignancy, rheumatological and infectious aetiologies was performed and resulted negative. (Table 2) , including a mutation in KRAS, which was reported previously to be associated with RALD [6] . Dideoxy Sanger sequencing confirmed the presence of a heterozygote mutation in the patient's PBMCs (c.38G > A; p. Gly13Asp, GGC!GAC). This mutation was not detected in her parents and healthy siblings. Sequencing of DNA from the patient's nails revealed that the genotype at this genomic position was homozygote wild-type, indicating a somatic mutation in the haematopoietic lineage (Fig. 1) .
Genetic evaluation
Immunological assessment
Immunological work-up at the age of 2 years revealed prominent monocytosis and lymphocytosis. Normal numbers of T and natural killer (NK) cells but increased B cells with an inverted ratio of CD4 were noted (Table 1) , as described previously for ALPS [17] . DNT cells were only mildly increased (2.6%) (normal below 1%). The patient's IgG and IgA levels were elevated with normal IgM. T cell proliferation in response to mitogen stimulation was normal.
Production of new T and B cells decreased in a RALD patient over time in concordance with clinical deterioration. To assess whether the process of non-malignant proliferation in our patient affected lymphocyte homeostasis, the amounts of sjTRECs and sjKRECs, markers of de-novo T and B cell production, respectively, were determined. Serial measurements of these markers in peripheral blood during 3 years revealed a significant decrease with time (Table 3 , Fig. 2) , suggesting a decreasing production of new B and T cells. Similarly, the ratio between B cells containing sjKREC and total B cells (cjKREC), declined over time (Table 3 ). The sjKREC/cjKREC ratio estimates the homeostasis between naive B cell production and peripheral B cell replication and when it favours cjKREC, as it did in our patient, this suggests diminished B cell production, increased peripheral proliferation, or both. The decline in B and T cell production over time was also evident clinically, as the patient suffered from severe infections requiring prolonged and recurrent hospitalizations.
TCR and BCR repertoires in a RALD patient are restricted. In order to examine peripheral clonality, TCR and BCR repertoires were analysed using several modalities. The TCR profile was assessed with the traditional TCR-Vb assay using flow cytometry. At the age of 3 years, the initial TCR analysis revealed a relatively normal Vb usage distribution (Fig. 3, upper panel) . However, 2 years later the TCR repertoire was abnormal, demonstrating several over-and under-represented Vb genes, and displaying overall a mildly skewed representation (over-expression was seen in VB1, VB3, VB9 and under-expression was seen in VB2, VB4, VB14, VB16,VB17 and VB21.3, Fig. 3, lower panel) . The BCR profile, examined by measurement of junctional diversity for a mixture of Vh-Jh pairings [18] , consistently exhibited a Gaussian-like distribution in the patients' peripheral blood performed at the ages of 4, 5 and 6 years (Fig. 4) . In order to characterize further the TCR and BCR repertoires, high-throughput immunosequencing of the TRG and IGH repertoires was performed on PBMCs from the patient and two healthy age-matched controls.
As seen in Fig. 4a , the patient's T cells displayed a more significantly restricted TRG repertoire than controls. The patient's calculated diversity indices (Table 4) clearly show increased clonality with decreased diversity in the patient's TCR repertoire compared to the two healthy controls. Shannon's entropy measures the uncertainty in predicting the identity of a single receptor sequence selected at random from the repertoire. The more diverse the repertoire, the higher Shannon's entropy. Our patient's Shannon's entropy index was lower than both controls for both TRB and IGH repertoires, reflecting restriction. Gini-Simpson's and Simpson's diversity indices calculate the evenness of distribution of individual receptors within a repertoire. The more evenly distributed the repertoire, the larger these indices are. For both TRG and IGH, the patient's repertoires were distributed less evenly than those of the controls. The top 100 clones in the patient's repertoire comprised 57% of all TRG clonotypes, whereas in the control samples the top 100 clones comprised 20 and 44% of all clonotypes. The patient's BCR repertoire (Fig. 4b ) demonstrated a similarly restricted repertoire compared to the healthy control, albeit to a lesser extent than the TCR. The diversity indices showed moderate restriction compared to healthy, agematched controls. The top 100 B cell clones in the patient's sample comprised slightly more than 50% of all IGH clonotypes, a substantially larger share than that comprised by the top 100 clones in either control (19 and 21%) . Vg and Vh gene usage profiles, harvested from the NGS data, demonstrated an abnormal repertoire when compared to the two healthy controls, similarly to the Vb usage profile depicted above (data not shown).
Discussion
RALD is an extremely rare disease characterized by monocytosis and non-malignant lymphoproliferation, which manifests with lymphadenopathy, massive splenomegaly, increased circulating B cells, hypergammaglobulinaemia and autoimmunity.
In some RALD patients, recurrent and at times invasive infections have been documented, suggestive of immune deficiency [7] . Hidden behind normal to elevated lymphocyte counts and hypergammaglobulinemia, this component of RALD has yet to be studied extensively. A deficiency in TCR and BCR repertoires is a critical factor in the pathogenesis, evolution and progression of many autoimmune diseases [10] . Indeed, abnormalities of antigen receptor repertoire diversity and complexity have been demonstrated in various autoimmune diseases [19] . The development of NGS technologies enabled analysis of these immune repertoires in various pathological conditions, including immunodeficiency [18, 19] and autoimmune disorders [20, 21] . The obtained analyses reached a depth that could not be achieved with previously available techniques. Fig. 2 . Signal joint T cell receptor excision circle (sjTREC) and signal joint kappa deleting receptor excision circle (sjKREC) copy numbers over time. Excision circle copy numbers (in log scale) as detected by reverse transcription-polymerase chain reaction (RT-PCR) in sequential measurements throughout disease progression compared to healthy controls. *Thirty-five healthy pediatric donors, median (controls were healthy children not taking chronic medications who came in for a routine paediatric visit and blood work. Their ages ranged between 8 and 12 years and 40% were female). TREC 5 T cell receptor excision circle; KREC 5 kappa deleting receptor excision circle; sj 5 signal joint; cj 5 coding joint; HD 5 healthy donors.
Applying high-throughput sequencing to our patient's lymphocytes, we found that the TCR repertoire in our RALD patient was constricted substantially compared to two healthy age-matched controls. A small group of expended clones occupy a considerable portion of the total receptor repertoire, constricting the remaining share reciprocally. Diversity indices, such as Shannon's entropy index and Simpson's diversity index, showed that our patient's TCR repertoire is significantly less diverse and more restricted compared with healthy age-matched controls.
Sequential measurements of sjTREC showed marked deterioration in de-novo T cell production, while sequential repertoire analyses demonstrated a worsening in TCR Vb gene usage abnormality over time. Together, these results provide further evidence that an ongoing process of peripheral oligoclonal T lymphoproliferation constricts and distorts the TCR repertoire as a whole in RALD.
In B cells, while BCR spectratyping (a crude measurement of junctional diversity within all B cells using the same V-J pairings) failed to demonstrate repertoire abnormalities in our patient, high-throughput sequencing revealed a constricted BCR repertoire. Unlike the TCR repertoire, which is dominated by a few massively expanded clones, the BCR repertoire appears to be restricted due to moderate expansions of many separate clones, resulting in a 'top-heavy' repertoire.sjKREC copy numbers, like sjTREC, declined dramatically over time in our patient, indicating a decrease in de-novo B cell production. In addition, the patient displayed a decreased sjKREC/cjKREC ratio with time, further supporting the concept of peripheral clonal proliferation skewing B cell homeostasis.
As reported above, this decline in immune competence, as manifested in both constrictions of the TCR and BCR repertoires as well as decreased de-novo lymphocyte production, was accompanied clinically by an increase in both the frequency and severity of infections suffered by our patient.
In this paper, we report for the first time, to our knowledge, the use of NGS to analyse the T and B cell receptor repertoires in a RALD patient harbouring a somatic KRAS mutation. Due to the extreme rarity of this syndrome, we could evaluate only one patient. In classical ALPS, patients are known to exhibit autoimmune clonal expanded cells, infiltrating haematopoietic organs [17] . Nevertheless, receptor diversity analysis of these cells was reported to be relatively normal [22] . Recently, it was shown that ALPS patients display a disturbed B lymphocytes selection that may trigger clonal expansion [23] , although this has yet to be studied in RALD. Immunophenotyping of peripheral blood of RALD patients showed characteristic polyclonal B cells [7] ; however, with the use of NGS we were able to show a restricted and clonal expansion of both TCR and BCR repertoires in one RALD patient. Our findings suggest that clonal expansion in RALD reciprocally restricts the remaining lymphocyte receptor repertoire, contributing to an immunodeficient state. This concept may be applicable to any syndrome that is characterized by autoimmunity.
No study to date, to our knowledge, has explored TREC or KREC markers of T and B cell production in RALD patients. We found that these two markers decreased gradually with time in the patient and were associated with both clinical immunodeficiency and clonal expansion. Some RALD patients have lived to the age of 50 years, whereas others succumbed to severe sepsis at an early age. TREC and KREC measurement, readily accessible to most 5Á27  0Á960  25  0Á57  HD1  7Á20  0Á999  893  0Á20  HD2  6Á30  0Á994  177  0Á44  IGH  Patient  6Á33  0Á997  295  0Á51  HD1  7Á38  0Á999  894  0Á19  HD2  7Á25  0Á999  802  0Á21 Shannon's entropy is a measurement of the richness and diversity of a repertoire, whereas Gini-Simpson's, Simpson's and Top 100 clonotypes provide different views into clone frequency distribution within a repertoire. HD 5 healthy donor. immunodeficiency laboratories, may help distinguishing between severe and mild RALD phenotypes, and allow monitoring of disease progression.
TCR and BCR repertoires using advanced genomic technologies, such as NGS as well as serial assays quantifying TRECs and KRECs, may help in understating the underlying immune dysfunction in RALD, ALPS and similar nonmalignant lymphoproliferative conditions. In addition, using these methodologies will enable more accurate classification of RALD patients [24, 25] and understanding of their homeostatic imbalance which, in turn, may pave the way to developing tailor-made follow-up and therapeutic approaches.
